Novartis touts Cosentyx win in debilitating skin condition. Can it challenge AbbVie's Humira?

Among its dozen FDA approvals for a variety of autoimmune disorders, AbbVie’s Humira has plenty of competition in most of its indications. In the debilitating skin condition hidradenitis suppurativa however, Humira is a solo act—a status it has enjoyed since its FDA nod in 2015.